ABSTRACT

Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies. In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens. The discovery of tumor antigens c

part |2 pages

Part 2 Human tumor antigens recognized by class I HLA-restricted T cells

part |2 pages

Part 3 Human tumor antigens recognized by class II HLA-restricted T cells